Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Eszopiclone (Lunesta) In San Francisco,.cde2"

Looking for quality documents?
event icon
Advancing TFF for Small Scale CGMP Production with KrosFlo RS 10
The latest in TFF system innovation by Repligen is here Get an inside look into a new purpose-built single-use TFF system designed for process development and CGMP production of mRNA, gene therapies, and personalized medicine- The KrosFlo RS 10  While much of the equipment that is being leveraged for these applications today are repurposed from applications supporting significantly larger volume ranges, this system truly satisfies the demand for smaller scales. With unique features including complete end-to-end automation and optional real-time concentration measurement, this TFF system may be exactly what you need to produce your next blockbuster drug.
corporate icon
XCell™ Lab System
NEW | Designed and engineered as a complete solution, the XCell™ Lab System integrates devices, controller and software, enabling low volume process intensification ready for scale-up.
news icon
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
external link icon
Repligen Corporation Names Tony Hunt as Next Chief Executive Officer
WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders. "Under Walter's leadership, Repligen has been transformed from a therapeutics company that produced bioprocessing products into a focused bioprocessing industry leader, providing high-value consumable products for biological manufacturers and creating substantial value for our stockholders," commented Karen A. Dawes, Chair of the Board of Repligen. "Walter has been a major force in building this outstanding company, and the Board and I, on behalf of the stockholders, thank Walter for his dedication, vision, and leadership." Ms. Dawes continued, "We are delighted to promote
publications icon
The SoloVPE System: Features and Benefits Overview Publication
publications icon
WuXi Biologics Expands Perfusion Cell Culture Capabilities
publications icon
DOC0198 ViPER ANLYTX 21 CFR Part 11 Compliance Position Software White Paper
external link icon
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million Orders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to range of $635-$645 million
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2023, covering the three- and nine-month fiscal periods ended September 30, 2023. Tony J. Hunt, Chief Executive Officer of Repligen said, “While the broader challenges that have dominated our industry over the last twelve months continued in the third quarter, we saw positive signs of recovery. Our order book strengthened by mid-quarter, delivering an overall book-to-bill of 1.07 by quarter end. In particular, orders from our Pharma customer base rebounded, with many of the projects highlighted on our second quarter call converting to purchase
publications icon
Immobilized rProtein A (IPA-400HC) Material Safety Data Sheet
external link icon
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter. Revenue for the quarter came in as expected with